Related Experiment Video
Updated: Jul 18, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Mandibular Langerhans cell histiocytosis]
1Service de Chirurgie Maxillo-faciale, EPS Habib Bourguiba, Sfax, Tunisie. morcheddhouib@yahoo.fr
Revue De Stomatologie Et De Chirurgie Maxillo-Faciale
|December 30, 2006
Summary
Langerhan's cell histiocytosis (LCH) is a rare condition. Mandibular LCH in young patients presents unique diagnostic and treatment challenges, often requiring histological confirmation and tailored interventions.
Area of Science:
- Oral and Maxillofacial Surgery
- Histiocytosis
- Oncology
Background:
- Langerhan's cell histiocytosis (LCH) is characterized by abnormal Langerhans cell proliferation.
- Mandibular involvement is the most common facial manifestation, particularly in individuals under 20.
- This report reviews LCH features, diagnosis, and treatment via case studies.
Observation:
- Two male patients, aged 10 and 55, presented with solitary mandibular LCH.
- Diagnosis was confirmed histologically following biopsy.
- Treatment varied: one patient had successful surgical resection, while the other received intralesional corticosteroid therapy for post-operative inflammation.
Findings:
- Mandibular LCH exhibits diverse clinical presentations, from dental mobility to gingival tumors.
- Radiological findings are variable, necessitating histological confirmation for diagnosis.
- Treatment strategies for solitary mandibular LCH range from observation to surgery, potentially combined with corticosteroids or radiotherapy.
Implications:
- Early and accurate diagnosis of mandibular LCH is crucial for effective management.
- Tailored treatment approaches based on lesion characteristics and patient age are essential.
- Further research into optimal LCH treatment protocols, especially for localized mandibular disease, is warranted.